83410-15-5

Usage

Uses

Used in Pharmaceutical Research and Development:
4-CHLORO-5-IODO-6-METHYLPYRIMIDINE is used as a precursor in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs with therapeutic applications. Its unique structural features allow for the creation of compounds that may exhibit novel pharmacological properties.
Used in Agrochemical Production:
In the agrochemical industry, 4-CHLORO-5-IODO-6-METHYLPYRIMIDINE is used as a starting material for the synthesis of various agrochemicals, potentially leading to the development of new pesticides or herbicides with improved efficacy and selectivity.
Used in Organic Synthesis:
4-CHLORO-5-IODO-6-METHYLPYRIMIDINE serves as a versatile intermediate in organic synthesis, where its reactivity and structural attributes are leveraged to construct a wide range of organic compounds for various applications, including but not limited to, materials science, specialty chemicals, and fine chemicals.
Used in Chemical Research:
4-CHLORO-5-IODO-6-METHYLPYRIMIDINE is utilized in chemical research to explore its reactivity and to understand the effects of its substituents on the properties of the resulting compounds. This research can lead to insights that are valuable for the design of new chemical processes and the discovery of new materials or pharmaceutical agents.

Upstream product

• 56-04-2 6-methyl-2-thiouracil 
• 3524-87-6 4-hydroxy-6-methylpyrimidine 
• 7752-74-1 4-hydroxy-5-iodo-6-methylpyrimidine 
• 3524-87-6 6-methyl-3H-pyrimidin-4-one 
• 7752-74-1 5-iodo-6-methyl-3H-pyrimidin-4-one 

Downstream Products

• 83410-18-8 4-Amino-5-iod-6-methyl-pyrimidin 
• 912353-72-1 C₂₇H₂₈ClFN₄O₂ 
• 912353-86-7 C₃₁H₂₈ClFN₄O₂ 
• 912353-71-0 C₂₆H₂₆ClFN₄O₂ 
• 912354-03-1 C₂₅H₂₄ClFN₄O₂ 
• 912354-05-3 C₂₇H₂₇ClFN₅O₃ 
• 912353-73-2 C₂₇H₂₈ClFN₄O 
• 912353-74-3 C₂₉H₃₃ClFN₅O 
• 912353-78-7 C₂₉H₂₆ClFN₄O 
• 912354-47-3 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-5-iodo-6-methylpyrimidin-4-amine 
• 1436405-33-2 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenoxy)-5-iodo-6-methylpyrimidine 
• 1436405-35-4 N-((5-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenoxy)-6-methylpyrimidin-5-yl)ethynyl)furan-2-yl)methyl)-2-(methylsulfonyl)ethanamine 
• 1436405-34-3 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenoxy)-5-ethynyl-6-methylpyrimidine 
• 1436405-31-0 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-5-ethynyl-6-methylpyrimidin-4-amine 

Relevant academic research and scientific papers

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors

36 new compounds with the typical skeleton of 4-anilino-5-vinyl/ethynyl pyrimidine, 4-anilino-3-cyano-5-vinyl/ethynyl/phenyl pyridine, and m-amino-N-phenylbenzamide, are designed, synthesized and selectively tested on EGFR, ErbB-2 kinases, and A-549, HL60 cells growth inhibition. Results from the bioactivity and chemical structures yield preliminary structure-activity relationships (SARs). The most potent 5-ethynylpyrimidine derivative 20a has an IC50 value of 45 nM to EGFR kinase. Several compounds of other series also show IC50 values 1 μM for EGFR and 5 μM for A-549 and HL60 cells growth inhibition.

5-Alkynyl-pyridines

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification

NEW 5-ALKYNYL-PYRIDINES

5-alkynyl-pyridine of general formula (I) which are inhibitors of the activity of PI3K alpha, and their use in the treatment of diseases characterized by excessive or abnormal cell proliferation, such as cancer.

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of P13Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS

The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors

A structure-activity relationship study of 4-anilinopyrimidines for dual EGFR/Her-2 inhibitor has resulted in the identification of 4-anilino-5-alkenyl or 5-alkynyl-6-methylpyrimidine derivatives that have exhibited effective inhibitory activity against both enzymes. The presence of 5-alkenyl or 5-alkynyl moiety bearing terminal hydrophilic group played important role for inhibition of these enzymes. Selected compounds in the series demonstrated some activity against Her-2 dependent cell line (BT474).